Women may be more susceptible to adverse events

BMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7071.1552c (Published 14 December 1996) Cite this as: BMJ 1996;313:1552
  1. Maggie Phillips
  1. Medical director Travellers' Medical and Vaccination Centre, Adelaide, Australia

    EDITOR,—The methodology that P J Barrett and colleagues used in their study comparing adverse events associated with mefloquine with those associated with chloroquine plus proguanil for antimalarial prophylaxis1 is similar to that used in a study that Kass and I carried out.2 We, however, compared mefloquine with doxycycline, which is widely used by Australians and North Americans as the alternative to mefloquine for travellers to chloroquine …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription